Abstract 213P
Background
Renal cell carcinoma with sarcomatoid de-differentiation (sRCC) is a highly aggressive form RCC with trials reporting a poor median OS of 5 to 12 months. Recent genomics profiling of sRCC suggest that Srcc is not a single entity but is highly influenced by the parent RCC subtype from which its shares histological characteristic. A recent meta-analysis suggests that sRCC is associated with a higher cancer specific mortality, poorer progression free and overall survival but not gender and average age. A population-based study of 879 patients taken from the SEER data showed that the 5-year DSS were 77.7%, 67.8%, 35.4%, and 3.5% for patients with stage I, II, III, and IV disease at diagnosis.
Methods
A retrospective analysis was conducted on patients diagnosed with sRCC from 1997 to 2018. Disease characteristics, treatment outcomes and adverse events were retrieved from digital medical records. Overall survival and progression free survival were estimated using Kaplan Meier method.
Results
62 patients with a diagnosis of sRCC were identified. 72% (n = 45) were males. Median age was 56 years old on diagnosis. Majority of patients were Chinese at 72%. 52%(N = 32) were metastatic on diagnosis with 18%(n = 12) were diagnosed with initially early stages(I-II). 80%(n = 47) were symptomatic from the cancer on diagnosis with at least 1 symptom of haematuria, flank pain, fever, loss of weight. Majority of the patients (n = 54) had were clear cell rcc with sarcomatoid component while the 7% (n = 5) were papillary rcc. The median overall survival for the metastatic group was 1.26 years with 53% having had VEGF inhibitors as first line treatment while about a quarter had no treatment.
Conclusions
We currently report the disease characteristics and treatment of patients diagnosed with sRCC in our tertiary cancer centre. In our study, about half of the cohort was metastatic on diagnosis with another 20% having early stage on initial diagnosis. The overall survival outcomes of this real world metastatic sRCC group is promising and appears better than prior reports. More research is needed to better understand this group of patients with poor outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ravindran Kanesvaran.
Funding
Has not received any funding.
Disclosure
R. Kanesvaran: Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Ipsen; Honoraria (self), Advisory / Consultancy: Eisai; Honoraria (self), Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy: Johnson and Johnson. All other authors have declared no conflicts of interest.
Resources from the same session
107P - The efficacy of adjuvant chemotherapy according to the risk classification of recurrence based on the systemic inflammatory markers in patients with colorectal cancer liver metastases
Presenter: Masatsune Shibutani
Session: Poster display session
Resources:
Abstract
108P - Influence of liver metastasis locations on overall survival in patients with colorectal cancer
Presenter: Takayuki Sone
Session: Poster display session
Resources:
Abstract
109P - 18F-FDG PET/CT textural features as predictors of outcomes in patients with primary advanced colorectal cancer
Presenter: Jing Yang
Session: Poster display session
Resources:
Abstract
110P - D3 lymph node dissection may be necessary in clinical stage I right colon cancer
Presenter: Woong Bae Ji
Session: Poster display session
Resources:
Abstract
111P - Is preoperative chemoradiotherapy necessary for all patients with upper rectal cancer: One center retrospective study
Presenter: Jasur Madyarov
Session: Poster display session
Resources:
Abstract
112P - A retrospective analysis of the association between perioperative, post adjuvant carcinoembryonic antigen level and prognosis in stage III colorectal cancer
Presenter: Ryotaro Kozuki
Session: Poster display session
Resources:
Abstract
113P - Dicer contributes to chemoresistance in colorectal cancer via regulating a set of miRNAs and their downstream mRNAs
Presenter: Liang-Yi Hung
Session: Poster display session
Resources:
Abstract
114P - Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial
Presenter: Jun Zhu
Session: Poster display session
Resources:
Abstract
115P - Expression of Ki-67 as a prognostic factor in patients with colorectal cancer
Presenter: Kuantkan Zhabagin
Session: Poster display session
Resources:
Abstract
116P - Clinical significance and converionrate relevance of RAS genetic mutation analysis for unresectable colorectal liver metastases: A single-center retrospective study
Presenter: Meiling Ji
Session: Poster display session
Resources:
Abstract